Aurinia Pharmaceuticals Inc. (AUPH) on Decifer

Decifer ranks AUPH number 137 of 265 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 16% and those returns have been improving.
• Revenue is growing about 20% a year and profits grew 5,250% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• 16 percent returns and 5250 percent profit growth are notable but 10 momentum and no growth reason mean it is not investable for thesis-driven growth.

The current read

The evidence on AUPH lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full AUPH research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.